BeiGene (NASDAQ:BGNE – Get Rating) had its price objective hoisted by Guggenheim to $210.00 in a research note issued on Tuesday, Stock Target Advisor reports. Guggenheim’s price objective would suggest a potential upside of 2.06% from the company’s previous close. Other research analysts also recently issued reports about the stock. JPMorgan Chase & Co. reiterated […]
